Brenig Therapeutics Initiates First-in-Human Trial of LRRK2 Inhibitor BT-267 for Parkinson Disease
Neurology Live,
Brenig Therapeutics is testing BT-267, a potential best-in-class LRRK2 inhibitor, in a first-in-human trial for Parkinson's…
Brenig Therapeutics is testing BT-267, a potential best-in-class LRRK2 inhibitor, in a first-in-human trial for Parkinson's…
References Fischer O. Miliaere Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmassige Veraenderung der…